PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.
Excess Equipment Sale for BioUtah Members
Excess Equipment Sale for BioUtah Members
PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the quarterly period ended June 30, 2022.
PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
PolarityTE announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor
PolarityTE to Effectuate 1-for-25 Reverse Stock Split
PolarityTE announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding common stock.
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the three-month period ended March 31, 2022.
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
PolarityTE announced that the U.S. FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND.
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
SALT LAKE CITY, May 3, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE,” or “COVER […]
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]
PolarityTE Announces $5.0 Million Registered Direct Offering
PolarityTE Announces $5.0 Million Registered Direct Offering
